SAB Biotherapeutics Inc SABS.OQ SABS.O is expected to show no change in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for SAB Biotherapeutics Inc is for a loss of 51 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for SAB Biotherapeutics Inc is $8.00, about 62.4% above its last closing price of $3.01
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.82 | -0.80 | -1.09 | Missed | -36.9 |
Mar. 31 2025 | -1.07 | -1.03 | -0.56 | Beat | 45.6 |
Dec. 31 2024 | -1.16 | -1.23 | Missed | -5.3 | |
Sep. 30 2024 | -1.09 | -1.09 | -1.12 | Missed | -2.8 |
Jun. 30 2024 | -1.12 | -1.13 | -0.79 | Beat | 30.1 |
Mar. 31 2024 | -0.96 | -0.96 | -0.60 | Beat | 37.5 |
Dec. 31 2023 | -0.64 | -0.62 | -3.38 | Missed | -445.2 |
Sep. 30 2023 | -1.16 | -1.17 | -1.00 | Beat | 14.3 |
This summary was machine generated October 31 at 21:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments